Andrew Tait Joins Sigma7 to Lead Integrated Risk and Life Sciences

New York, NY, July 19, 2022 — Risk services advisory Sigma7 today announced that Andrew Tait had joined the organization as Partner, Integrated Risk and Life Science Practice Leader, a new executive position for the rapidly scaling company. Tait joined Sigma7 from Marsh Specialty, where he was Managing Director and Lead Senior Consultant.

In his new position, Tait will lead the development and delivery of Sigma7’s front-end client services that enable leaders to synthesize risk visualization and quantification across risk domains, making clear the optimal use of limited risk capital across the enterprise. Sigma7’s managed risk model brings together and extends services from the company’s family of best-in-class specialist brands that include Paragon Risk Engineering, RWH Myers, Strategia Worldwide and Risk & Strategic Management, Corp.

Sigma7 offers extensive technical, sector and geographic risk expertise and serves over 350 clients globally, from bases in nine countries.

Tait brings Sigma7 a distinguished background of helping leading global organizations navigate risk. Tait’s leadership background includes Enterprise Risk Management, Supply Chain Risk Management, Business Continuity/Disaster Recovery program design & implementation, and risk management and insurance program development in support of global clients.
Earlier in his career, Tait built Core Risks Ltd, a premier specialty risk advisory firm, which he sold to Jardine Lloyd Thompson Group (JLT) in 2014. He held advisory leadership and Life Sciences Leadership positions at JLT. Tait was formerly the Global Risk Manager at Sanofi Aventis, based in Paris, France.

Tait has been a property insurance broker, property loss control engineer, and business continuity consultant. He has worked in Europe for several years, holds a BSME, an MBA, and is a Licensed Professional Engineer in fire protection.

Andrew Hersh, CEO of Sigma7, said, “Sigma7 is committed to delivering our clients a superior capability that enables them to continuously optimize risk decisions in strategic and tactical matters. Having worked with Andrew for several years and competed against him for many more, I’m certain that Andrew is the very best in the industry to lead Sigma7’s client-facing integrated risk capabilities as well as our Life Sciences industry practice.”